Welcome! Defeating Merkel cell carcinoma begins here.
The critical first step is to find a Merkel cell carcinoma specialist.
It is critical that each case be reviewed by a multidisciplinary team, including surgical oncologists, radiation oncologists, medical oncologists, and dermatologists with significant experience in managing MCC, in order to develop a plan for the patient.
To find healthcare professionals experienced with Merkel cell carcinoma, start with our list of verified specialists.Find a Specialist
Make sure your primary care team is knowledgeable and takes action.
Merkel cell carcinoma is rare, and it's common for many medical professionals to be unsure of where to start. When a diagnosis occurs, it is imperative that your medical team is knowledgeable and able to carry out an MCC specialist's plan.
Our clinical team recommends that all healthcare providers follow the NCCN guidelines for MCC to bring them up to speed on MCC and how to care for MCC patients.Get the Guide
Consider joining a patient-based group
A diagnosis of Merkel cell carcinoma is a life-changing experience. Support from others—in the form of advice, recommendations for local healthcare providers, or sharing personal victories—can help ease the burden many MCC patients and their families feel.
We encourage you to make connections; it’s been proven to help.Get Support
The latest advancements in treatment
Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient
Managing MCC that recurs in patients who are immune suppressed due to an organ transplant (kidney, heart, etc) is a special challenge, as the immune therapies that block the PD1 pathway will cause rejection of the transplanted organ. This case shows the capacity of local immune therapy (with an inje...
Recurrence and mortality rates with different treatment approaches of Merkel cell carcinoma: a systematic review and meta-analysis
This is a comprehensive analysis of 52 previously published studies across 1804 patients with Merkel cell carcinoma, addressing which approaches are most effective in preventing MCC recurrences. Because national databases do not capture recurrence data (only death) such studies must be done by local...
Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe
Although MCC fortunately does not often spread to the brain, this is an especially difficult site to treat. This manuscript summarizes results from four patients that closely mimic our own experience in Seattle. That is, there is a reasonable chance that patients with MCC that has spread to the brai...